R. Gralla

2.3k total citations · 1 hit paper
38 papers, 1.9k citations indexed

About

R. Gralla is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, R. Gralla has authored 38 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in R. Gralla's work include Lung Cancer Treatments and Mutations (15 papers), Cancer Treatment and Pharmacology (10 papers) and Lung Cancer Research Studies (10 papers). R. Gralla is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Cancer Treatment and Pharmacology (10 papers) and Lung Cancer Research Studies (10 papers). R. Gralla collaborates with scholars based in United States, United Kingdom and France. R. Gralla's co-authors include Peter H. Wiernik, D L Trump, T Ohnuma, David A. Van Echo, James R. Baker, Ross C. Donehower, R B Weiss, Daniel D. Von Hoff, B Leyland-Jones and Mark G. Kris and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Annals of Oncology.

In The Last Decade

R. Gralla

36 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Hypersensitivity reactions from taxol.

1990 951 citations R B Weiss, Ross C. Donehower et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
R. Gralla United States	15	1.1k	469	427	339	196	38	1.9k
T Ohnuma United States	16	812 0.7×	202 0.4×	554 1.3×	354 1.0×	73 0.4×	40	1.7k
B Leyland-Jones United States	16	847 0.8×	197 0.4×	418 1.0×	351 1.0×	78 0.4×	42	1.7k
Robert J. Belt United States	20	1.5k 1.4×	459 1.0×	789 1.8×	169 0.5×	229 1.2×	59	2.6k
Manon Huizing Belgium	29	2.2k 2.0×	457 1.0×	664 1.6×	180 0.5×	365 1.9×	98	3.0k
Rut Isacson Israel	10	1.3k 1.2×	441 0.9×	378 0.9×	296 0.9×	73 0.4×	22	1.9k
R B Weiss United States	20	1.1k 0.9×	465 1.0×	628 1.5×	361 1.1×	51 0.3×	37	2.5k
Olga Lyass Israel	14	669 0.6×	463 1.0×	427 1.0×	570 1.7×	239 1.2×	18	1.8k
G. N. Hortobágyi United States	23	1.7k 1.6×	543 1.2×	573 1.3×	63 0.2×	253 1.3×	106	2.7k
George P. Stathopoulos Greece	28	1.4k 1.2×	457 1.0×	689 1.6×	391 1.2×	124 0.6×	105	2.6k
Jinee Rizzo United States	16	1.2k 1.1×	645 1.4×	652 1.5×	107 0.3×	108 0.6×	26	1.8k

Countries citing papers authored by R. Gralla

Since Specialization

Citations

This map shows the geographic impact of R. Gralla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Gralla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Gralla more than expected).

Fields of papers citing papers by R. Gralla

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Gralla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Gralla. The network helps show where R. Gralla may publish in the future.

Co-authorship network of co-authors of R. Gralla

This figure shows the co-authorship network connecting the top 25 collaborators of R. Gralla. A scholar is included among the top collaborators of R. Gralla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Gralla. R. Gralla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gralla, R., et al.. (2009). Determining issues of importance for patients with breast cancer: Results of a web-based study in 1,072 patients to enhance the content validity for the development of a new health-related quality of life (QL) instrument, the Breast Cancer Symptom Scale (BCSS). Journal of Clinical Oncology. 27(15_suppl). e20615–e20615. 2 indexed citations

Gralla, R., Patricia J. Hollen, Philip Kuruvilla, et al.. (2005). P-327 Can performance status (PS) be determined accurately bypatients? Results of a prospective trial evaluating ECOG and Karnofsky PS as well as patient-rated PS in non-small cell lung cancer (NSCLC). Lung Cancer. 49. S201–S202. 2 indexed citations

Gralla, R., Patricia J. Hollen, James T. Symanowski, et al.. (2003). 905 Documenting symptom palliation with chemotherapy using the LCSS-Meso: Results from the randomized trial of pemetrexed plus cisplatin vs cisplatin alone in patients with malignant pleural mesothelloma. European Journal of Cancer Supplements. 1(5). S272–S272. 3 indexed citations

Gralla, R., Peter Harper, Stephen A. Johnson, & F.M. Delgado. (1999). Vinorelbine (Navelbine®) in the treatment of non-small-cell lung cancer: Recent developments in combination chemotherapy and radiotherapy. Annals of Oncology. 10. S47–S51. 4 indexed citations

Kris, Mark G., Katherine M.W. Pisters, Robert J. Ginsberg, et al.. (1995). Effectiveness and toxicity of preoperative therapy in stage iiia non-small cell lung cancer including the memorial sloan-kettering experience with induction mvp in patients with bulky mediastinal lymph node metastases (Clinical n2). Lung Cancer. 12. S47–S57. 7 indexed citations

Gralla, R. & Rebecca A. Clark. (1993). Progress in controlling emesis with cancer chemotherapy. Supportive Care in Cancer. 1(4). 178–181. 1 indexed citations

Grant, Scott, et al.. (1992). Single-agent chemotherapy trials in small-cell lung cancer, 1970 to 1990: the case for studies in previously treated patients.. Journal of Clinical Oncology. 10(3). 484–498. 61 indexed citations

Divgi, Chaitanya, Mark G. Kris, Francisco X. Real, et al.. (1991). Phase I and Imaging Trial of Indium 111-Labeled Anti-Epidermal Growth Factor Receptor Monoclonal Antibody 225 in Patients With Squamous Cell Lung Carcinoma. JNCI Journal of the National Cancer Institute. 83(2). 97–104. 240 indexed citations

Gralla, R.. (1990). New directions in non-small cell lung cancer.. PubMed. 17(4 Suppl 7). 14–9. 14 indexed citations

10.

Weiss, R B, Ross C. Donehower, Peter H. Wiernik, et al.. (1990). Hypersensitivity reactions from taxol.. Journal of Clinical Oncology. 8(7). 1263–1268. 951 indexed citations breakdown →

11.

Scher, Howard I., Brenda Shank, Robert Chapman, et al.. (1989). Randomized trial of combined modality therapy with and without thymosin fraction V in the treatment of small cell lung cancer. Lung Cancer. 5(6). 35–35. 11 indexed citations

12.

Kris, Mark G., Joseph O’Connell, & R. Gralla. (1986). Phase I trial of taxol given as a 3-hour infusion every 21 days. Journal of Ethnopharmacology. 18(3). 299–299. 40 indexed citations

13.

Wertheim, M. S., Mark G. Kris, & R. Gralla. (1985). Phase I trial and clinical pharmacologic study of 10-ethyl-10-deaza-aminopterin (10-EdAM). Proceedings of the American Association for Cancer Research. 26. 6 indexed citations

14.

O’Connell, Joseph, Mark G. Kris, & R. Gralla. (1985). Phase I trial of taxol given as a three hour infusion every three weeks. Proceedings of the American Association for Cancer Research. 26. 2 indexed citations

15.

Kris, Mark G., R. Gralla, Leonard Kalman, et al.. (1985). Randomized trial comparing vindesine plus cisplatin with vinblastine plus cisplatin in patients with non-small cell lung cancer, with an analysis of methods of response assessment. Lung Cancer. 1(3-4). 79–79. 70 indexed citations

16.

Allen, Jeffrey C., R. Gralla, Laura Reilly, Michael Kellick, & Charles Y.F. Young. (1985). Metoclopramide: dose-related toxicity and preliminary antiemetic studies in children receiving cancer chemotherapy.. Journal of Clinical Oncology. 3(8). 1136–1141. 81 indexed citations

17.

Kelsen, David P., R. Gralla, Edgar Cheng, & Nael Martini. (1983). Vindesine in the treatment of malignant mesothelioma: a phase II study.. PubMed. 67(9). 821–2. 23 indexed citations

18.

Casper, E. S., R. Gralla, Richard J. Kaufman, & Charles W. Young. (1981). Aclacinomycin-A: Phase I trial in patients with solid tumors. Proceedings of the American Association for Cancer Research. 22.

19.

Gralla, R., E. S. Casper, Robert B. Golbey, & Charles W. Young. (1979). Phase I and preliminary phase II studies with N-(phosphonacetyl)-L-aspartic acid (PALA). Proceedings of the American Association for Cancer Research. 20. 3 indexed citations

20.

Tan, Carlyn, R. Gralla, Peter G. Steinherz, & Charles W. Young. (1978). Phase I study of chlorozotocin. Proceedings of the American Association for Cancer Research. 19. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact